載入中
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
前收盤價
US$4.11
−US$0.07 · -1.67%
盤中時間採用ET。市場資料可能有所延遲。
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
日內區間
目前US$4.11
52週區間
目前US$4.11
盤中時間採用ET。市場資料可能有所延遲。
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
日內區間
目前US$4.11
52週區間
目前US$4.11
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3557.7萬 USD | 756.6萬 USD | 512.4萬 USD | 903.2萬 USD | 1200萬 USD |
| 銷貨成本 | 344.1萬 USD | 274萬 USD | 74.6萬 USD | 72.5萬 USD | 47.2萬 USD |
| 毛利 | 3213.6萬 USD | 482.6萬 USD | 437.8萬 USD | 830.7萬 USD | 1152.8萬 USD |
| 研究與開發 | 885.5萬 USD | 1184萬 USD | 2029.5萬 USD | 1219.8萬 USD | 1592.9萬 USD |
| 銷售、一般及管理費用 | 3522萬 USD | 5882.2萬 USD | 4730.5萬 USD | 1740.5萬 USD | 2697.9萬 USD |
| 營業費用 | 4407.5萬 USD | 7074.5萬 USD | 7013.7萬 USD | 2960.3萬 USD | 4243.6萬 USD |
| 利息收入 | 92.9萬 USD | 141.7萬 USD | 274萬 USD | 47.6萬 USD | 12.3萬 USD |
| 利息支出 | 774.2萬 USD | 941.2萬 USD | 396.2萬 USD | 217.2萬 USD | 429.5萬 USD |
| 折舊和攤銷 | 78.1萬 USD | 126.9萬 USD | 83.6萬 USD | 71.8萬 USD | 47.2萬 USD |
| 營業利益 | −1193.9萬 USD | −6591.9萬 USD | −6575.9萬 USD | −2129.6萬 USD | −3090.8萬 USD |
| 淨利 | −1788.6萬 USD | −7657.9萬 USD | −6699.5萬 USD | −2448.7萬 USD | −3508萬 USD |
公司資料更新於 2026年10月11日。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWC
Avantis Total Equity Markets ETF 1AVTMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
